This page will list articles and news about new cancer treatments approved in Canada.
AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer (December 2019)
Health Canada approves PERJETA® (pertuzumab) for the treatment of HER2-positive early breast cancer after surgery (September 2018)
Health Canada Approves GAZYVA® for Previously Untreated Advanced Follicular Lymphoma (July 2018)
ALECENSARO® (alectinib) approved by Health Canada for first-line treatment of ALK-positive lung cancer (June 2018)
Lynparza® (olaparib) Receives New Indication for BRCA-Mutated Metastatic Breast Cancer (May 2018)
Health Canada Approves RITUXAN® Subcutaneous Formulation for Canadians with Chronic Lymphocytic Leukemia (March 2018)